Journal article

Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment

Paul Mitchell, Neil Bressler, Quan V Doan, Chantal Dolan, Alberto Ferreira, Aaron Osborne, Elena Rochtchina, Mark Danese, Shoshana Colman, Tien Y Wong



Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the number of individuals in Australia who would have been likely to avoid legal blindness or visual impairment due to neovascular age-related macular degeneration over a 2-year period as a result of intravitreal ranibizumab injections. The modelling approach used existing data for the incidence of neovascular age-related macular degeneration in Australia and outcomes from ranibizumab trials. Blindness and visual impairment were defined as visua..

View full abstract


Funding Acknowledgements

This study was funded by Novartis AG and Genentech, Inc. Novartis AG and Genentech, Inc. participated in the design and conduct of the study, in the distribution of the raw data to Outcomes Insights, in the analysis and interpretation of the data and in the preparation of the manuscript. Novartis AG and Genentech, Inc. reviewed the manuscript before submission. Third-party medical writing assistance, but not editorial content sufficient to meet International Committee of Medical Journal Editors (ICMJE) authorship criteria, was funded by Novartis AG.